Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Ablynx : Belgian biotech Ablynx scores big hit with blood disease drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:15am CEST

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion (£825 million).

Ablynx said its caplacizumab medicine met the primary and secondary goals in a late-stage trial testing the treatment in patients with acquired thrombotic thrombocytopenic purpura (aTTP).

This included a 74 percent relative reduction in the percentage of patients with aTTP-related death, a recurrence of aTTP or at least one major thromboembolic event during the study drug treatment period.

Shares in Ablynx jumped 25 percent in early trade on what Jefferies analysts described as near best-case results.

The brokerage assumes caplacizumab will launch in mid-2018 in Europe and the first half of 2019 in the United States and will generate worldwide peak sales of $400 million. Caplacizumab is wholly-owned by Ablynx, so sales should be highly profitable.

"These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available," said Ablynx CEO Edwin Moses.

(Reporting by Ben Hirschler; Editing by Edmund Blair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
10/17 ABLYNX : 17/10/2017 ablynx announces launch of proposed global offering
10/17 ABLYNX : Announces launch of proposed global offering
10/16 ABLYNX : 16/10/2017 ablynx establishes subsidiary in the usa and appoints a gene..
10/16 ABLYNX : 16/10/2017 publication in accordance with article 14 of the belgian law..
10/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/16 ABLYNX : Establishes subsidiary in the usa and appoints a general manager
10/13 ABLYNX : 13/10/2017 publication in accordance with article 14 of the belgian law..
10/13 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
10/06 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More news
News from SeekingAlpha
12:48p YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
10/03 YOUR DAILY PHARMA SCOOP : Pfizer A Buy, Our Ablynx Pick Successful, VBLT, DVAX, ..
10/02 Ablynx's caplacizumab successful in late-stage study in rare blood disorder; ..
Financials (€)
Sales 2017 59,0 M
EBIT 2017 -55,7 M
Net income 2017 -75,2 M
Finance 2017 8,18 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 17,2x
EV / Sales 2018 18,6x
Capitalization 1 025 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 18,4 €
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX63.99%1 206
INCYTE CORPORATION14.00%24 360
QUINTILES IMS HOLDINGS INC31.30%21 440
CELLTRION, INC.--.--%20 806
LONZA GROUP64.29%19 850
ALNYLAM PHARMACEUTICALS, INC.228.53%10 889